IMR Press / EJGO / Volume 35 / Issue 6 / DOI: 10.12892/ejgo25262014

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Borderline epithelial ovarian tumors: a single center experience
Show Less
1 Department of Obstetrics and Gynecology, Kanuni Sultan Suleyman Research and Teaching Hospital, Istanbul
2 Department of Obstetrics and Gynecology, Antalya University Faculty of Medicine, Antalya (Turkey)
Eur. J. Gynaecol. Oncol. 2014, 35(6), 692–695;
Published: 10 December 2014

Aim: To evaluate the clinical outcomes of the patients treated for borderline ovarian tumor (BOT). Materials and Methods: In this retrospective study, records of the patients between November 2001 and December 2012 who underwent surgery and whose final pathological diagnosis were BOT were retrieved. Results: During the study period, 78 patients were diagnosed as BOT. The pathological diagnoses of the tumors were serous in 26 (33.3%) and mucinous in 52 patients (66.6 %), respectively. Accuracy of frozen section diagnosis was observed in 63 of 89 patients (70.7%). Sixty-eight women (87.1%) underwent complete staging procedure. According to final pathological diagnoses, Stage IA, IB, and IC were found in 52 (67%), five (6.5%), and seven (9%) patients, respectively. FIGO Stages IIC and IIIC were found in one case in each (1.25%). Remaining 12 patients were classified as unstaged (15%). The median follow-up time was 63 months. The authors observed only one recurrence (1.3%) and that patient died of disease. Conclusion: The survival rate in patients with BOTs confined to the ovary is excellent. Surgical staging procedure can be omitted in the patients with grossly apparent Stage I mucinous tumors.
Borderline ovarian tumor
Surgical staging
Clinical outcome
Back to top